PNT
Closed
Point Biopharma Global Inc
12.5
0.0 (0.00%)
Last Update: 29 Dec 2023 17:30:00
Yesterday: 12.5
Day's Range: 12.5 - 12.5
Send
sign up or login to leave a comment!
When Written:
7.41
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company that focuses on developing radiopharmaceutical therapies for the treatment of cancer. The company was founded in 2019 and is headquartered in Toronto, Canada, with additional offices in the United States and Europe.
POINT Biopharma's lead product candidate is a radiopharmaceutical therapy called Lutetium Lu 177 Dotatate, which is being developed for the treatment of neuroendocrine tumors. The company is also developing other radiopharmaceutical therapies for the treatment of various types of cancer.
The company's approach to drug development involves using targeted radiation therapy to deliver high doses of radiation directly to cancer cells while minimizing damage to healthy tissues. This approach has the potential to provide more effective and less toxic treatments for cancer patients.
POINT Biopharma has partnerships with several leading academic institutions and research organizations, including the University of California, Los Angeles, and the European Organization for Research and Treatment of Cancer. The company has also received funding from several venture capital firms and other investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
POINT Biopharma's lead product candidate is a radiopharmaceutical therapy called Lutetium Lu 177 Dotatate, which is being developed for the treatment of neuroendocrine tumors. The company is also developing other radiopharmaceutical therapies for the treatment of various types of cancer.
The company's approach to drug development involves using targeted radiation therapy to deliver high doses of radiation directly to cancer cells while minimizing damage to healthy tissues. This approach has the potential to provide more effective and less toxic treatments for cancer patients.
POINT Biopharma has partnerships with several leading academic institutions and research organizations, including the University of California, Los Angeles, and the European Organization for Research and Treatment of Cancer. The company has also received funding from several venture capital firms and other investors.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!